Skip to main content
Bio Solution Co.,Ltd. logo

Bio Solution Co.,Ltd. — Investor Relations & Filings

Ticker · 086820 ISIN · KR7086820008 KO Manufacturing
Open in API
Filings indexed 214 across all filing types
Latest filing 2019-03-08 AGM Information
Country KR South Korea
Listing KO 086820

About Bio Solution Co.,Ltd.

https://bio-solution.co.kr/

Bio Solution Co., Ltd. is a biotechnology company focused on the development, manufacturing, and sale of cell therapy products. The company's core activities involve cell-based biotechnology, producing therapeutics such as autologous chondrocyte treatments for cartilage regeneration. In addition to its therapeutic offerings, Bio Solution develops human tissue models and provides alternative testing solutions. The company also manufactures and distributes a portfolio of bio-laboratory products, including ready-to-use kits, staining solutions, and various reagents for molecular biology research and development applications.

Recent filings

Filing Released Lang Actions
주주총회소집공고
AGM Information Classification · 1% confidence The document is a 'Notice of Annual General Meeting' (주주총회소집공고) for the company 'Biosolution' (주식회사바이오솔루션). It contains the agenda for the meeting, details on voting procedures, proxy forms, and management information regarding board activities and business outlook. This document is a standard proxy statement and meeting notice sent to shareholders to inform them of the upcoming AGM and request their participation/votes. In the context of the provided categories, this fits the 'Proxy Solicitation & Information Statement' (PSI) classification, as it serves to solicit proxies and provide necessary information for the meeting.
2019-03-08 Korean
주식매수선택권행사
Share Issue/Capital Change Classification · 1% confidence The document is a regulatory filing from BioSolution regarding the exercise of stock options (주식매수선택권 행사). It details the number of shares exercised, the exercise price, the impact on total shares, and the schedule for new share issuance. This type of disclosure regarding changes in capital structure due to stock option exercises falls under the 'Share Issue/Capital Change' category.
2019-02-22 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 1% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on the Granting of Stock Options) submitted to the Financial Services Commission/Korea Exchange. It details the issuance of stock options to employees, including the number of shares, exercise price, and legal basis. This type of disclosure regarding the issuance of new rights or capital-related instruments is classified as a regulatory filing under the RNS category, as it does not fit into specific categories like DIRS (which is for director dealings) or SHA (which is for share issues/capital changes in the context of equity issuance).
2019-02-12 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for BioSolution. It outlines the date, location, and specific agenda items (such as financial statement approval, director/auditor appointments, and remuneration limits). This document serves as the official proxy solicitation and information statement provided to shareholders to inform them of the upcoming meeting and the matters to be voted upon. It fits the definition of a Proxy Solicitation & Information Statement (PSI).
2019-02-12 Korean
기타경영사항(특허권취득)(자율공시)
Regulatory Filings Classification · 1% confidence The document is a short, voluntary disclosure (자율공시) regarding the acquisition of a patent by BioSolution. It does not fit into financial reporting categories like 10-K or IR, nor is it a report announcement. As it is a specific regulatory disclosure regarding company operations/intellectual property that does not fall into the other specialized categories, it is classified as a general regulatory filing.
2019-01-29 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 1% confidence The document is a regulatory filing from a Korean company (Biosolution) announcing a significant change (over 30%) in revenue or profit structure. This is a standard disclosure requirement for listed companies in Korea to report preliminary financial results before the final audit is completed. Since it provides key financial highlights (revenue, operating profit, net income) and explains the reasons for the change, it fits the definition of an Earnings Release (ER). FY 2018
2019-01-18 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.